Impact of antirecurrent therapy with antigestagens for uterine fibroids on the breast in reproductive-aged women


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To evaluate the impact of antirecurrent therapy for uterine fibroids with the use of gynestril (mifepristone 50 mg) on the breast in reproductive-aged women. Subjects and methods. Examinations were made in 110 reproductive-aged women who received antirecurrent therapy with gynestril (mifepristone) at a dose of 50 mg per day in continuous mode for 3 months after laparoscopic myomectomy. Benign breast dysplasia (BBD) was diagnosed based on general clinical examination, check-up, palpation, and ultrasonography of the breast in all the patients before and after gynestril administration, and three months later. Results. Breast examination revealed that prior to gynestril use, 61.82% of the women had subjective signs (mastalgia, mastodynia) of BBD that was objectively verified by ultrasonography in 47.27% of the patients. The use of gynestril was ascertained to be associated with a significant (p < 0.05) decline in the number of women with subjective signs of BBD: from 61.85 to 30% after completion of 3-month therapy and to 31.82% 3 months after treatment termination and in that of women with objective signs of diffuse breast changes: from 40.91 to 21.82% after completion of 3-month therapy and to 19.84% 3 months later. Conclusion. It was established that there was a significant decrease in the detection rate of BBD predominantly as a diffuse form during antirecurrent therapy with gynestril for uterine fibroids.

Full Text

Restricted Access

About the authors

Vladislava Aleksandrovna Novikova

Kuban State Medical University

Email: vladislavan@mail.ru
MD, professor of the Department of Obstetrics, Gynecology and Perinatology, Faculty of Postgraduate Education

Grigory Artemovich Penzhoyan

Kuban State Medical University

Email: pga05@mail.ru
Doctor of Medical Sciences, Professor, Head of the Department of Obstetrics, Gynecology and Perinatology, Faculty of Advanced Studies and Postgraduate Training of Specialists

Vadim Aleksandrovich Khorolsky

Kuban State Medical University

Email: vadim23_67@mail.ru
associate professor of the Department of Obstetrics, Gynecology and Perinatology, Faculty of Postgraduate Education

Tatyana V. Skladanovskaya

Volgograd State Medical University

Email: yanechka2000@yandex.ru
associate professor of the Department of Obstetrics and Gynecology and Perinatology, Faculty of Postgraduate Education

Vladislav Viktorovich Ponomarev

Kuban State Medical University

Email: 11vik@mail.ru
Doctor of Medical Sciences, Professor of the Department of Obstetrics, Gynecology and Perinatology, Faculty of Advanced Studies and Postgraduate Training of Specialists.

References

  1. Приказ Минздравсоцразвития России №808н от 2 октября 2009 г. «Об утверждении Порядка оказания акушерско-гинеко логической помощи». [Order of the Health Ministry of Russia №808n dated October 2, 2009. „On approval of the provision of obstetric care.” (in Russian)]
  2. Приказ Министерства здравоохранения Российской Федерации (Минздрав России) от 1 ноября 2012 г. № 572н «Об утверждении Порядка оказания медицинской помощи по профилю акушерство и гинекология (за исключением использования вспомогательных репродуктивных технологий)». [The Russian Federation Ministry of Health Order (Ministry of Health of Russia) dated November 1, 2012 № 572n „On approval of the provision of medical care on the profile of obstetrics and gynecology (except for the use of assisted reproductive technologies).” (in Russian)].
  3. Идрисова Э.А., Бабгоева О.Х., Коган Е.А., Гуриев Т.Д. Клинико-морфологические особенности фиброзно-кистозной болезни при сочетании с лейомиомой матки и аденомиозом. Российский вестник акушера-гинеколога. 2011; 11(6): 28-32. [Idrisov E.A., Babgoeva O.Kh., Kogan E.A., Guriev T.D. Clinico-morphological features of fibrocystic disease in combination with uterine leiomyoma and adenomyosis. Rossiyskiy vestnik akushera-ginekologa. 2011; 11(6): 28-32. (in Russian)].
  4. Зацепин А.В., Новикова В.А., Васина И.Б. Сравнение эффективности фармакологических методов антирецидивного лечения миомы матки после консервативной миомэктомии. Кубанский научный медицинский вестник. 2012; 2: 88-92. [Zatsepin, AV, Novikov VA, Vasin IB comparing the effectiveness of pharmacological methods of antirecidial treatment of uterine fibroids after conservative myomectomy. Kubanskiy nauchnyiy meditsinskiy vestnik. 2012. 2: 88-92. (in Russian)]
  5. Звичайний М.А., Воронцова А.В., Чилова А.А., Федотовских И.В. Гиперпластический синдром репродуктивной системы у женщин в перименопаузе: тактика консервативной терапии и реабилитации. Гинекология. 2014; 16(1): 44-8. [Zvychayny M.A., Vorontsova A.V., Chilova A.A., Fedotovskaya I.V. Hyperplastic reproductive syndrome in perimenopausal women: the tactics of conservative treatment and rehabilitation. Gynekologiya. 2014; 16(1): 44-8. (in Russian)]
  6. Khan A.T., Shehmar M., Gupta J. K. Uterine fibroids: current perspectives. Int. J. Womens Health. 2014; 6: 95-114. doi: 10.2147/IJWH.S51083.
  7. Wagenfelda A., Saundersb Ph.T.K., Whitakerc L., Critchleyc H.O.D. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin. Ther. Targets. 2016; 20(9): 1045-54. Available at: http:// dx.doi.org/10.1080/14728222.2016.1180368
  8. Obr A.E., Edwards D.P. The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol. Cell. Endocrinol. 2012; 357: 4-17.
  9. Hagan C.R., Knutson T.P., Lange C.A. A common docking domain in progesterone receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. Nucleic Acids Res. 2013; 41(19): 8926-42.
  10. Brisken C. Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat. Rev. Cancer. 2013; 13(6): 385-96.
  11. Sartor O., Figg W.D. Mifepristone: antineoplastic studies. Clin. Obstet. Gynecol. 1996; 39(2): 498-505.
  12. Klijn J.G., Setyono Han B., Foekens J.A. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 2000; 65(10-11): 825-30.
  13. Chabbert-Buffet N., Meduri G., Bouchard P., Spitz I.M. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum. Reprod. Update. 2005; 11(3): 293-307. doi: 10.1093/ humupd/dmi002.
  14. Engman M., Skoog L., Söderqvist G., Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum. Reprod. 2008; 23(9): 2072-9.
  15. Yu S., Yang X., Zhu Y., Xie F., Lu Y., Yu T. et al. Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: Comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex. Sci. Rep. 2015; 5: 7830. doi: 10.1038/srep07830.
  16. Tieszen Ch.R., Goyeneche A.A., Brandhagen B.A.N., Ortbahn C.T., Telleria C.M. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer. 2011; 11: 207. Available at: http://www.biomedcentral.com/1471-2407/11/207

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies